# reload+after+2024-01-22 17:32:59.025163
phone§855.724.0450
longBusinessSummary§The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
maxAge§86400
priceHint§2
yield§0.0022
totalAssets§101202232
navPrice§31.9081
currency§USD
category§Health
ytdReturn§-0.029938199
beta3Year§0.76
fundFamily§ALPS
fundInceptionDate§1419897600
legalType§Exchange Traded Fund
threeYearAverageReturn§-0.1466986
fiveYearAverageReturn§0.018738901
exchange§PCX
quoteType§ETF
shortName§ALPS Medical Breakthroughs ETF
longName§ALPS Medical Breakthroughs ETF
firstTradeDateEpochUtc§1420036200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§77dc5ba5-7d93-30eb-9731-e619e0fc568d
gmtOffSetMilliseconds§-18000000
trailingPegRatio§None
